AbCellera Biologics

Founder‑CEO Carl Hansen has led the company from an academic concept to a scaled platform with top‑tier partners and now a clinical pipeline; in 2025 AbCellera added Sarah Noonberg, M.D., Ph.D., as CMO to strengthen clinical execution.

The company continues to secure multi‑target collaborations with leading pharmas (e.g., AbbVie in oncology in January 2025 and a 2024 expansion with Eli Lilly across multiple therapeutic areas). We view the team as scientifically strong and long‑term oriented, with credible capital stewardship thus far.

Execution risk now shifts to running efficient, informative trials and making sharp capital allocation calls between internal and partner programs.